However, the combination of THC and NQO1 inhibitor exerted a superior effect on tumor growth than THC monotherapy in ESCC-PDX, suggesting that NQO1 expression might be a critical biomarker of THC response in ESCC patients [53]. The gene discussed is NQO1; the disease is esophageal squamous cell carcinoma.